Xpert ® HIV-1 Qual XC
A molecular point-of-care test that delivers actionable results in around 90 minutes
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
product image
10 Tests
Unit price
Product is not available for purchase in your region.
Collection devices
product image
Sarstedt Minivette POCT 100 μl(Pack of 100)
Unit price
Product is not available for purchase in your region.
Error adding items to cart. If this error persists, please contact Digital Support

The Need

  • Acute HIV infections are characterized by the lack of anti-HIV antibodies and the presence of high levels of virus in the blood and a risk of transmission.1
  • Maternal HIV antibodies can persist in a child up to 18 months preventing the use of serological testing for diagnosis. HIV infection in infants can be definitively confirmed only with HIV NAT2 (e.g. PCR) testing.
  • A highly sensitive HIV qualitative PCR test is needed for early diagnosis of HIV infections in high-risk populations and infants.
1 National Institute of Health, Fact Sheet: The stages of HIV Infection. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/early-acuteand-recent-hiv-infection#:~:text=Acute%20HIV%20infection%20occurs%20soon%20after%20transmission%20and,after%20infection%2C%20during%20which%20anti-HIV%20antibodies%20become%20detectable. Accessed Sept 2023.
2 World Health Organization. (2021). Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. World Health Organization. https://apps.who.int/iris/handle/10665/340190.

The Solution

  • The Xpert HIV-1 Qual XC (extended coverage) test is a nucleic acid amplification test for the qualitative detection of HIV-1 total nucleic acids, on the automated GeneXpert® system and directly from whole blood or dried blood spot samples.
  • It is intended to aid in the diagnosis of HIV-1 infection in infant, adolescent, and adult populations that can be performed in a laboratory or at the point of care.

The Impact

  • Improve access to HIV testing: Designed for near-patient testing in any setting allowing faster delivery of results and medical follow up. Simple sample collection, testing, and results in ~90 minutes.3,4
  • Accurate results for infant diagnosis and acute infections: Earlier detection provides an important opportunity to improve management in all age groups.3,4
  • Reduce time from testing to treatment: Fast track initiation of treatment, reduce risk of transmission and increase retention in care with point-of-care HIV-1 nucleic acid tests.3,4
3 Meulbroek, et al. 2018 HIV Medicine BCN Checkpoint: same-day confirmation of reactive HIV rapid test with Point Of Care HIV-RNA accelerates linkage to care and reduces anxietyDOI: 10.1111/hiv.12595
4 Bianchi et al, 2019 Lanvet HIV Evaluation of a routine point-of-care intervention for early infant diagnosis of HIV: an observational study in eight African countries.